Maria Fernanda Escobar

Dr. Maria Fernanda Escobar


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2017 in Emerging Infectious Diseases
Verified
Journal Article
Open access
MEMaria Fernanda Escobar
Maria Fernanda Escobar
ANAlbaro J. Nieto
Albaro J. Nieto
SLSara Loaiza-Osorio
Sara Loaiza-Osorio
JBJuan S. Barona
Juan S. Barona
FRFernando Rosso
Fernando Rosso
In 2015 in Colombia, 60 pregnant women were hospitalized with chikungunya virus infections confirmed by reverse transcription PCR. Nine of these women required admission to the intensive care unit because of sepsis with hypoperfusion and organ dysfunction; these women met the criteria for severe acute maternal morbidity. No deaths occurred. Fifteen women delivered during acute infection; some received tocolytics to delay delivery until after the febrile episode and prevent possible vertical transmission. As recommended by a pediatric neonatologist, 12 neonates were hospitalized to rule out vertical transmission; no clinical findings suggestive of neonatal chikungunya virus infection were observed. With 36 women (60%), follow-up was performed 1 year after acute viremia; 13 patients had arthralgia in >2 joints (a relapse of infection). Despite disease severity, pregnant women with chikungunya should be treated in high-complexity obstetric units to rule out adverse outcomes. These women should also be followed up to treat potential relapses.

27 March 2018 in The Journal of Maternal-Fetal & Neonatal Medicine
Verified
Journal Article
Closed access
MEMaria Fernanda Escobar
Maria Fernanda Escobar
DMDaniela Montes
Daniela Montes
APAlejandra Pérez
Alejandra Pérez
SLSara Loaiza-Osorio
Sara Loaiza-Osorio
ACAlbaro José Nieto Calvache
Albaro José Nieto Calvache
Background: Hepatic rupture is a complication during pregnancy that, although rare, accounts for high morbidity and mortality rates. It is mainly associated with severe preeclampsia and HELLP syndrome. Incidence is estimated to be at one per 67,000 births or one per 2000 patients with preeclampsia/eclampsia/HELLP, mainly in multiparous women; women in their 40s; after 32 weeks of gestation; and during the first 15 h postpartum. Cases: This article exposes the institutional experience at Fundación Valle del Lili in Cali, Colombia, in managing and treating hepatic rupture associated with severe preeclampsia and HELLP syndrome in three patients in the 30th, the 26th, and the 27th week of gestation, not resulting in maternal death. Discussion: A search in Pubmed, Embase, and Ovid from 2000 to 2017 resulted in 35 cases reported in either pregnant or puerperal women. Hepatic rupture is a rare complication in pregnancy associated with preeclampsia and HELLP syndrome. Its pathophysiology is attributed to the presence of vasospasm due to an increase in concentration and sensitivity to circulating vasopressors during pregnancy. There is no standard management, but surgery reduces mortality significantly. It includes endovascular management, partial hepatectomy, or transplant (only one patient required a liver transplant in our search). The most used techniques have been ligation of the hepatic artery, embolization of the hepatic artery, and examination, packing, and drainage of hepatic lesion for bleeding control (27 cases were treated with laparotomy with evacuation of hematoma and hemostasis and four cases were treated with embolization of the hepatic artery). Hepatic artery occlusion both by surgery ligation and by embolization through interventional radiology has reported successful and failing results during pregnancy Conclusion: Management of pathologies as hepatic rupture associated with severe preeclampsia and HELLP syndrome has to be clearly protocolized for prompt diagnosis and early management. Furthermore, it has to be carried out through multidisciplinary teams in high-complexity obstetrics scenarios.

24 September 2018 in World Journal of Emergency Surgery
Verified
Journal Article
Open access
PDF file
RNRamiro Manzano Nunez
Ramiro Manzano Nunez
MEMaria Fernanda Escobar
Maria Fernanda Escobar
COClaudia P. Orlas
Claudia P. Orlas
JHJuan P. Herrera-Escobar
Juan P. Herrera-Escobar
SGSamuel M. Galvagno
Samuel M. Galvagno
COCarlos Albert Ordoñez
Carlos Albert Ordoñez
Morbidly adherent placenta (MAP), which includes accreta, increta, and percreta, is a condition characterized by the invasion of the uterine wall by placental tissue. The condition is associated with higher odds of massive post-partum hemorrhage. Several interventions have been developed to improve hemorrhage-related outcomes in these patients; however, there is no evidence to prefer any intervention over another. Resuscitative endovascular balloon occlusion of the aorta (REBOA) is an endovascular intervention that may be useful and effective to reduce hemorrhage and transfusions in MAP patients. The objective of this narrative review is to summarize the evidence for REBOA in patients with MAP. We posit that acute care surgeons can perform REBOA for patients with MAP.

12 May 2017 in Reproductive Health
Verified
Journal Article
Open access
PDF file
MEMaria Fernanda Escobar
Maria Fernanda Escobar
CFCarlos Eduardo Füchtner
Carlos Eduardo Füchtner
JCJavier Andrés Carvajal
Javier Andrés Carvajal
ANAlbaro José Nieto
Albaro José Nieto
AMAdriana Messa
Adriana Messa
SMSuellen Miller
Suellen Miller
The aim of this case series is to describe the experience of using the non-pneumatic anti-shock garment (NASG) in the management of severe Postpartum hemorrhage (PPH) and shock, and the value of implementing this concept in high-complexity obstetric hospitals. Descriptive case series of 77 women that received NASG in the management of PPH with severe hypovolemic shock from June 2014 to December 2015. Vital signs, shock index (SI), the lactic acid value and the base deficit were compared before and after NASG application. Fifty-six (77%) women had an SI > 1.1 at the time shock management was initiated; 96% had uterine atony. All women received standard does of uterotonics. The average time between the birth and NASG applications was 20 min. Forty-eight percent of women recovered haemodynamic variables in the first hour and 100% within the first 6 h; 100% had a SI < 1.0 in the first hour. The NASG was not removed until definitive control of bleeding was achieved, with an average time of use of 24 h. There were no mortalities. In this case series of women in severe shock, the NASG was an effective management device for the control of severe hypovolemic shock. It should be considered a first-line option for shock management.

31 March 2020 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
MEMaria Fernanda Escobar
Maria Fernanda Escobar
MHMaria A. Hincapie
Maria A. Hincapie
JBJuan S. Barona
Juan S. Barona
Recent metagenomics and microbiology studies have identified microorganisms that are typical of the fetoplacental unit. Considering this emerging evidence, the placenta, uterus, and the amniotic cavity are not sterile and not immune privileged. However, there is evidence for a beneficial interaction between active maternal immune system and the presence of commensal pathogens, which lead to an immune-tolerant state, thereby preventing fetal rejection. Multiple conditions associated with the loss of the normal flora are described (dysbiosis), which could result in perinatal and puerperal adverse events, including, directly or indirectly, postpartum hemorrhage. Altered flora when associated with a severe proinflammatory state and combined with patient's genetic and environmental factors confers a high-risk adverse outcome. Better understanding of the adverse role of dysbiosis in pregnancy outcome will improve maternal outcome.

24 April 2019 in International Journal of Gynecology & Obstetrics
Verified
Journal Article
Closed access
PDF file
ELEduard J. Langenegger
Eduard J. Langenegger
GTGerhard B. Theron
Gerhard B. Theron
DHDavid R. Hall
David R. Hall
CBCamilo Bello
Camilo Bello
MEMaria Fernanda Escobar
Maria Fernanda Escobar
THthe FIGO Committee for Safe Motherhood and Newborn Health
the FIGO Committee for Safe Motherhood and Newborn Health